EG20281A - Process for preparing heterocyclic cyclic amine derivatives useful in enhancing memory in patients suffering from dementia and alzheimer's disease - Google Patents

Process for preparing heterocyclic cyclic amine derivatives useful in enhancing memory in patients suffering from dementia and alzheimer's disease

Info

Publication number
EG20281A
EG20281A EG15592A EG15592A EG20281A EG 20281 A EG20281 A EG 20281A EG 15592 A EG15592 A EG 15592A EG 15592 A EG15592 A EG 15592A EG 20281 A EG20281 A EG 20281A
Authority
EG
Egypt
Prior art keywords
dementia
alzheimer
disease
patients suffering
cyclic amine
Prior art date
Application number
EG15592A
Other languages
English (en)
Inventor
Anabella Villalobos
Arthur Adam Nagel
Yuhpyng Liang Chen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of EG20281A publication Critical patent/EG20281A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EG15592A 1991-03-28 1992-03-26 Process for preparing heterocyclic cyclic amine derivatives useful in enhancing memory in patients suffering from dementia and alzheimer's disease EG20281A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67691891A 1991-03-28 1991-03-28

Publications (1)

Publication Number Publication Date
EG20281A true EG20281A (en) 1998-07-30

Family

ID=24716559

Family Applications (1)

Application Number Title Priority Date Filing Date
EG15592A EG20281A (en) 1991-03-28 1992-03-26 Process for preparing heterocyclic cyclic amine derivatives useful in enhancing memory in patients suffering from dementia and alzheimer's disease

Country Status (29)

Country Link
EP (1) EP0646115B1 (xx)
JP (3) JP2659107B2 (xx)
KR (1) KR0179054B1 (xx)
CN (1) CN1044242C (xx)
AT (1) ATE231505T1 (xx)
AU (2) AU658194B2 (xx)
BR (1) BR9205811A (xx)
CA (2) CA2195129C (xx)
CZ (1) CZ289756B6 (xx)
DE (1) DE69232907T2 (xx)
DK (1) DK0646115T3 (xx)
EG (1) EG20281A (xx)
ES (1) ES2188584T3 (xx)
FI (1) FI934223A (xx)
HU (1) HU225047B1 (xx)
IE (1) IE920980A1 (xx)
IL (3) IL116122A0 (xx)
MX (1) MX9201419A (xx)
MY (1) MY108885A (xx)
NO (1) NO304071B1 (xx)
NZ (3) NZ248946A (xx)
PL (3) PL170567B1 (xx)
PT (1) PT100300B (xx)
RU (1) RU2119920C1 (xx)
SG (1) SG49055A1 (xx)
UA (1) UA45944C2 (xx)
WO (1) WO1992017475A1 (xx)
YU (1) YU31392A (xx)
ZA (1) ZA922239B (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
CA2116117A1 (en) * 1991-08-22 1993-03-04 Hiroyuki Sueoka Benzisoxazole compound and use thereof
EP0535496A1 (en) * 1991-09-25 1993-04-07 Hoechst-Roussel Pharmaceuticals Incorporated (1-Indanon-2yl)methylpiperidines, intermediates and a process for their preparation and their use as medicaments
DK0669920T3 (da) * 1992-11-23 2003-05-26 Aventis Pharma Inc Substituerede 3-(aminoalkylamino)-1,2-benzisoxazoler og beslægtede forbindelser
US5494908A (en) * 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
GB9305623D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
DK0788500T3 (da) * 1994-10-26 2004-06-07 Pfizer Fremgangsmåder og mellemprodukter til fremstilling af 5,7-dihydro-3-[2-(1-benzylpiperidin-4-yl)ethyl]-6H-pyrrolo-[4,5-f],2-benzisoxazol-6-on
WO1996025414A1 (en) * 1995-02-15 1996-08-22 Pharmacia & Upjohn Company Imidazo[1,2-a]pyridines for the treatment of cns and cardiac diseases
CN1184478A (zh) * 1995-03-22 1998-06-10 大正制药株式会社 噻唑衍生物
WO1996039397A1 (en) * 1995-06-06 1996-12-12 Hoechst Marion Roussel, Inc. Benzisoxazole and indazole derivatives as antipsychotic agents
JPH09124643A (ja) * 1995-08-14 1997-05-13 Bristol Myers Squibb Co 抗うつ作用を有する１−アリールアルキル−４−（アルコキシピリジニル）−又は４−（アルコキシピリミジニル）ピペラジン誘導体
US5916902A (en) * 1995-09-13 1999-06-29 Pfizer Inc. Processes and intermediates for preparing 5, 7-dihydro-3- 2-(1-benzylpiperidin-4-yl)ethyl-!6H-pyrrolo- 4, 5-F!-1, 2-benzisoxazol-6-one
US5998415A (en) * 1995-11-02 1999-12-07 Merck Sharp & Dohme Ltd. Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation, and their use of as selective agonists of 5-HT1 -like receptors
FR2751412B3 (fr) * 1996-07-17 1998-09-25 Valbiofrance Methodes de diagnostic in vitro de maladies neurodegeneratives et trousses pour la mise en oeuvre de ces methodes
US6013654A (en) * 1997-08-14 2000-01-11 Pharmacia & Upjohn Company Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases
EP0976404A3 (en) * 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
HUP0104493A3 (en) 1998-09-30 2002-12-28 Takeda Pharmaceutical Drugs for improving vesical excretory strength
US6951873B1 (en) 1999-04-27 2005-10-04 Pfizer Inc. Methods for treating age-related behavioral disorders in companion animals
EP1050303A3 (en) * 1999-04-27 2003-01-15 Pfizer Products Inc. Methods and compositions for treating age-related behavioral disorders in companion animals
AU767726B2 (en) * 1999-04-30 2003-11-20 Pfizer Products Inc. Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
PT1209151E (pt) 1999-09-01 2007-05-31 Eisai R&D Man Co Ltd Derivados piperidina 4-substituídos.
EP1300395B1 (en) 2000-06-21 2009-09-02 Eisai R&D Management Co., Ltd. 4-substituted piperidine compound
EP1609783A1 (en) * 2004-06-17 2005-12-28 Neuropharma S.A.U. Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
EP1907384A2 (en) * 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
US20090318690A1 (en) 2006-04-28 2009-12-24 Eisai R&D Management Co., Ltd. Benzisoxazole Compound
BRPI0812491A2 (pt) * 2007-06-01 2014-12-02 Schering Corp Moduladores de gama secretase
JP5216912B2 (ja) 2008-04-29 2013-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物
JP5411927B2 (ja) 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
AP2739A (en) 2008-09-26 2013-09-30 Boehringer Ingelheim Int Azaindazole compounds as CCRI receptor antagonists
AU2009325902B2 (en) * 2008-12-12 2015-01-29 Idorsia Pharmaceuticals Ltd 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives
KR20120087923A (ko) 2009-10-21 2012-08-07 베링거 인겔하임 인터내셔날 게엠베하 Ｃｃｒ１ 수용체 길항제로서의 인다졸 및 피라졸로피리딘 화합물
WO2011056440A1 (en) 2009-10-27 2011-05-12 Boehringer Ingelheim International Gmbh Heterocyclic compounds as ccr1 receptor antagonists
CN109662964A (zh) 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
WO2012087782A1 (en) 2010-12-23 2012-06-28 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as ccr1 receptor antagonists
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN108658964B (zh) * 2012-11-21 2021-07-02 拉夸里亚创药株式会社 多晶型物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
RU2638155C1 (ru) * 2016-02-29 2017-12-12 Общество С Ограниченной Ответственностью "Сай Фарма" Производные бензо[d]изоксазола и их применение
CA3228411A1 (en) * 2021-08-10 2023-02-16 Xiaomin Zhang Sulfonamide derivative, preparation method therefor and medical use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3488353A (en) 1967-05-29 1970-01-06 Sterling Drug Inc New 1-((2-azaindolyl)-lower-alkyl) 4-substituted-piperazines
JPS51136666A (en) * 1975-05-19 1976-11-26 Dainippon Pharmaceut Co Ltd Process for preparing 3-aminoalkyl-1,2-benzisoxazole derivatives.
US4396770A (en) * 1982-04-09 1983-08-02 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines
IL66866A (en) * 1982-04-09 1987-08-31 Hoechst Roussel Pharma 1-(3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl)-4-(substituted)-piperazines and-piperidines,a process for the preparation thereof,and pharmaceutical compositions containing them
US4489075A (en) * 1982-05-15 1984-12-18 Pfizer Inc. Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants
PH22302A (en) * 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
JPS63234065A (ja) * 1987-03-23 1988-09-29 Mitsubishi Rayon Co Ltd 包接能を有する高分子組成物
JPH0657707B2 (ja) * 1987-05-25 1994-08-03 吉富製薬株式会社 ピペリジン化合物
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4980365A (en) * 1987-07-13 1990-12-25 Hoechst-Roussel Pharmaceuticals Inc. N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
ES2055036T3 (es) * 1988-02-19 1994-08-16 Lilly Co Eli Antagonistas tetrazolicos de receptores de aminoacidos excitadores.
JPH0283375A (ja) * 1988-09-21 1990-03-23 Dainippon Pharmaceut Co Ltd ２−置換ピペラジニル−２−（１，２−ベンズイソキサゾール−３−イル）酢酸誘導体
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
ATE201669T1 (de) * 1991-04-17 2001-06-15 Upjohn Co Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten

Also Published As

Publication number Publication date
NZ248946A (en) 1995-04-27
ZA922239B (en) 1993-09-27
RU2119920C1 (ru) 1998-10-10
UA45944C2 (uk) 2002-05-15
HUT68357A (en) 1995-06-28
WO1992017475A1 (en) 1992-10-15
JPH06500794A (ja) 1994-01-27
JP2659107B2 (ja) 1997-09-30
MY108885A (en) 1996-11-30
IL101327A (en) 1998-06-15
CA2195129C (en) 2002-09-10
IL116122A0 (en) 1996-01-31
EP0646115A1 (en) 1995-04-05
PL170567B1 (pl) 1997-01-31
ES2188584T3 (es) 2003-07-01
YU31392A (sh) 1994-12-28
FI934223A0 (fi) 1993-09-27
JP3051076B2 (ja) 2000-06-12
JP2000154185A (ja) 2000-06-06
DE69232907T2 (de) 2003-05-15
IL101327A0 (en) 1992-11-15
NO933445L (no) 1993-09-27
NZ242151A (en) 1994-10-26
DE69232907D1 (de) 2003-02-27
CA2107105A1 (en) 1992-09-29
CN1044242C (zh) 1999-07-21
PT100300B (pt) 1999-09-30
MX9201419A (es) 1992-10-01
JPH10158264A (ja) 1998-06-16
HU225047B1 (en) 2006-05-29
AU1878292A (en) 1992-11-02
PL171914B1 (pl) 1997-06-30
NZ250987A (en) 1997-06-24
CA2195129A1 (en) 1992-09-29
EP0646115B1 (en) 2003-01-22
BR9205811A (pt) 1994-06-28
CA2107105C (en) 2003-10-07
AU658194B2 (en) 1995-04-06
IE920980A1 (en) 1992-10-07
NO933445D0 (no) 1993-09-27
FI934223A (fi) 1993-09-27
PL171915B1 (pl) 1997-06-30
AU2178895A (en) 1995-09-07
CZ395892A3 (en) 1994-04-13
ATE231505T1 (de) 2003-02-15
KR0179054B1 (en) 1999-03-20
IL116122A (en) 1998-10-30
CZ289756B6 (cs) 2002-04-17
DK0646115T3 (da) 2003-04-22
AU674477B2 (en) 1996-12-19
CN1065267A (zh) 1992-10-14
HU9302733D0 (en) 1993-12-28
NO304071B1 (no) 1998-10-19
SG49055A1 (en) 1998-05-18
PT100300A (pt) 1993-08-31

Similar Documents

Publication Publication Date Title
EG20281A (en) Process for preparing heterocyclic cyclic amine derivatives useful in enhancing memory in patients suffering from dementia and alzheimer's disease
TWI224595B (en) New benzazepine derivatives, drugs containing these and use of the same for producing drugs
CA2189007A1 (en) Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
ZA91918B (en) 17beta-substituted-4-aza-5alpha-androstan-3-one derivatives and process for their preparation
FI102756B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 6H-bentsfuro[3a,3,3-ef][2]bentsatsepiinijohdannaisten valmistamiseksi
FI101376B1 (fi) Menetelmä 3-bentsyyliamino-2-fenyylipiperidiinijohdannaisten valmistamiseksi
PT88656A (pt) Process for preparing 4-aminopyridine derivatives
HU910731D0 (en) Process for producing 4-(amino-methyl)-piperidine derivatives as well as pharmaceutical preparatives containing said derivatives as active substance
DK671588D0 (da) Bisphenylalkylpiperazinderivater og fremgangsmaade til fremstilling deraf
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
DK104388A (da) Hidtil ukendte 2-(2,3-dihydro-2-oxo-3-benzofuranyl)-eddikesyrederivater, fremgangsmaade til deres fremstilling og farmaceutiske midler indeholdende dem
ATE53839T1 (de) 2,3-dihydro-3-phenyl-benzofuran-2-onacetamidderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ZA924888B (en) Process for the synthesis of enantiomers of 3-aminochroman compounds